Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Background Pancreatic cancer often presents as locally advanced (LAPC) or borderline
resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is …

Simple Summary Due to the availability of effective combination chemotherapies such as
gemcitabine/nab-paclitaxel (GNP) or FOLFIRINOX, neoadjuvant treatment of borderline …

Simple Summary Metastatic PC often represents a complex decision-making moment for
oncologists, particularly due to the general conditions of the patients, age, and the potential …

Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …

Purpose. Irreversible electroporation (IRE) has been demonstrated to be a safe and effective
method for locally advanced pancreatic cancer (LAPC). The aim of this study was to …

Abstract Background Although FOLFIRINOX (5-Fluorouracil+ leucovorin+ irinotecan+
oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer …

Background Locally advanced pancreatic cancer (LAPC) is a devastating disease and
irreversible electroporation (IRE) is a non-thermal ablation method that is especially suitable …

Pancreatic carcinoma (PC) is one of the leading causes of cancer-related deaths worldwide.
Despite early detection and advances in therapeutics, the prognosis remains dismal. The …

Background Current systemic therapies for metastatic pancreatic ductal adenocarcinoma
are associated with poor outcomes with a 5-year overall survival rate under 5%. We aimed …